Preparation and Characterization of Chitosan Nanoparticles for Zidovudine Nasal Delivery.
Zidovudine (AZT) is the antiretroviral drug most frequently used for the treatment of Acquired Immunodeficiency Syndrome. Its low oral bioavailability demands the development of innovative strategies to overcome the first pass metabolism. The nasal route is an option for enhanced therapeutic efficacy and to reduce the extent of the first-pass effect. In this article, AZT loaded chitosan nanoparticles were prepared by a modified ionotropic gelation method with sodium tripolyphosphate. The increase proportion of CS (NP1 10:01 (w/w)) promoted the formation of smaller nanoparticles (260 nm), while raising the proportion of TPP (NP2 5:1 w/w) increased the nanoparticles size (330 nm). The incorporation of AZT increased the nanoparticles size for both AZT-loaded nanoparticles AZT-loaded NP1 (406 nm) and AZT-loaded NP2 (425 nm). The incorporation of AZT into NP1 did not change the electrophoretic mobility, however, in AZT-loaded NP2 there was a significant increase. The positive surface of the nanoparticles is very important for the mucoadhesive properties due interaction with the sialic groups of the mucin. Nuclear resonance magnetic data showed that the higher concentration of chitosan in the nanoparticles favored the interaction of few phosphate units (pyrophosphate) by ionic interaction Scanning electron microscopy, revealed that the nanoparticles are nearly spherical shape with porous surface. The entrapment efficiency of AZT, was 17.58% ± 1.48 and 11.02% ± 2.05 for NP1 and NP2, respectively. The measurement of the mucoadhesion force using mucin discs and nasal tissue obtained values of NP1 = 2.12 and NP2 = 4.62. In vitro permeation study showed that the nanoparticles promoted an increase in the flux of the drug through the nasal mucosa. In view of these results, chitosan nanoparticles were found to be a promising approach for the incorporation of hydrophilic drugs and these results suggest that the CS-containing nanoparticles have great potential for nasal AZT administration.
Mariana Da Silva
Mda S
Barbi
Flávia Chiva
FC
Carvalho
Charlene Priscila
CP
Kiill
Hernane Da Silva
Hda S
Barud
Sílvia Helena
SH
Santagneli
Sidney José Lima
SJ
Ribeiro
Maria Palmira Daflon
MP
Gremião
D000281:Administration, Intranasal; D000818:Animals; D019380:Anti-HIV Agents / Q000737:chemistry* / Q000493:pharmacokinetics; D048271:Chitosan / Q000737:chemistry*; D004337:Drug Carriers / Q000737:chemistry* / Q000493:pharmacokinetics; D009077:Mucins / Q000378:metabolism; D053758:Nanoparticles / Q000737:chemistry*; D009297:Nasal Mucosa / Q000378:metabolism; D019906:Nuclear Magnetic Resonance, Biomolecular; D010539:Permeability; D013552:Swine; D015215:Zidovudine / Q000737:chemistry* / Q000493:pharmacokinetics
D019380:Anti-HIV Agents; D004337:Drug Carriers; D009077:Mucins; D015215:Zidovudine; D048271:Chitosan